In the following interview, conducted at the 2026 American Urological Association Annual Meeting in Washington, DC, Sarah P. Psutka, MD, MSc, reflects on her talk regarding frailty and surgical ...

In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.

Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC. The novel hybrid design used in the phase 2 ARASEC trial (NCT05059236) 1 —and ...

The 2025 AUA Census documents significant geographic maldistribution of the urologic workforce—with 62% of US counties lacking a urologist—alongside a median practitioner age of 54 and generational ...

ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality ...

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI ...

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA. In this episode, ‘Comparative PSMA PET Tracer ...

PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics. In the final episode of this commentary, ...

This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient ...

Song Jiang, MD, PhD, discusses the balance between efficacy and safety data when considering the role for BCG/ICI combinations in BCG-naive NMIBC.

ODAC’s deliberations centered on whether rPFS improvement without demonstrated OS benefit constituted clinically meaningful benefit in PTEN-deficient mHSPC, concluding benefit outweighed risk by vote.

A cCR required negative imaging and no viable tumor on re-TURBT, and was achieved in 19/49 patients, with two subsequent intravesical recurrences and no distant failures reported. Twelve-month end ...